dEEGtal strengthens governance and advances clinical validation across three continents

Geneva-based dEEGtal has appointed neurotechnology entrepreneur and investor Ann Bunnenberg to its board of directors, as the AI-powered brain signal platform advances clinical studies across Switzerland, Spain, and the United States ahead of a CHF 4–5 million seed round.

Geneva-based dEEGtal, which develops AI-powered software to improve care in neurology and psychiatry, has appointed Ann Bunnenberg as an independent member of its board of directors. A medical device entrepreneur, venture investor, and lawyer with deep experience in neurotechnology, Bunnenberg brings expertise in product development, international commercialization, and strategic partnerships at a pivotal moment in the company’s development.

The appointment coincides with a period of significant clinical momentum. dEEGtal has validated its software on data collected from seven epilepsy centers across Europe and the United States in the context of a pre-incorporation academic research project, accumulating pre-clinical evidence on approximately 2,000 patients. The company has since established three active clinical collaborations: a study at a first seizure unit in Basel evaluating the platform in a real-world clinical context; an ongoing study at Vall d’Hebron Hospital in Barcelona targeting approximately 350 patients in an emergency center setting; and a partnership with UTMB in Galveston, Texas, from which its US clinical trials will be led.

The platform combines large-scale EEG datasets collected across leading European and American clinical centers with advanced AI models, targeting faster and more accurate identification of patients at risk of epilepsy following a first seizure, a critical decision point where current diagnostic tools frequently fall short. The company raised over CHF 1 million in seed funding in December 2024, anchored by a CHF 750,000 contribution from the Wyss Center in Geneva.

A CHF 4–5 million seed round is currently open and expected to close in Q2 2026, which will fund US clinical trials and position dEEGtal as a commercial-stage company in that market. Beyond epilepsy, the company plans to extend its large brain signal model to additional neurological and psychiatric conditions.